Navigation Links
Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
Date:5/28/2009

precision. Brain scans are administered at eight-week intervals post-treatment. Cotara has been generally well tolerated with an acceptable safety profile in clinical studies completed to date.

The main objectives of the open label Phase I dosing and dosimetry study at U.S. brain cancer centers are to confirm the maximum tolerated dose, to determine radiation dosimetry and to assess overall patient survival, progression free survival and the proportion of patients alive at six months following Cotara administration. Dosimetry data presented at the 2008 ASCO Annual Meeting showed that Cotara delivered 100-fold more radiation to the tumor as compared to other organs. Expanded data from this study has been accepted for an oral presentation at the Society of Nuclear Medicine Annual Meeting on June 16, 2009 in Toronto, Canada.

Cotara Presentation Details:

Reference #: 150240

Publication No.: 445

Abstract Title: Dosimetry of phase I interstitial 131I-chTNT-1/B MAb (Cotara) for the treatment of recurrent glioma

Accepted to: ISRTRD Integrated Session (Oral)

Session Info: Dosimetry/Radiobiology IV: Targeted, Diagnostic and Therapeutic Agents

Tuesday, June 16

12:30 PM - 2:00 PM

Room 701B

About Cotara(R)

Cotara is an experimental treatment for brain cancer that links a radioactive isotope to a targeted monoclonal antibody designed to bind to the DNA histone complex that is exposed by dead and dying cells found at the center of solid tumors. Cotara's targeting mechanism enables it to bind to the dying tumor cells, delivering its radioactive payload to the adjacent living tumor cells and essentially destroying the tumor from the inside out, with minimal radiation exposure to healthy tissue. Cotara is delivered using convection-enhanced delivery (CED), an NIH-developed method that targets the specific tumor site in the brain. In a
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
2. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
3. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
4. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
5. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
6. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
7. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
8. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
9. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
10. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
11. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... RESTON, Va. (PRWEB) October 22, 2014 ... Healthcare Innovation , which is dedicated to distribute ... efficiency of healthcare delivery worldwide announced the development ... in which patients expect when receiving healthcare. These ... definition for patient-centered care: “providing care that is ...
(Date:10/22/2014)... During the Western United States’ worst ... dangerously low, Southern Oregon’s water is proving resistant to ... lowest mountain snow pack on record in 2014, remain ... autumn.* That was the observation of journalist-hikers Art Bernstein ... Southern Oregon,” during an interview with water advocate Sharon ...
(Date:10/22/2014)... Weight Your Body’s Way , In a world where a ... certainly can be difficult to choose the right weight loss ... doing it the healthy way? Set aside the fads and ... exercise regularly, and choose foods with the most nutritional benefits. ... to exercise more and eat less. Despite the number of ...
(Date:10/22/2014)... Prussia, PA (PRWEB) October 22, 2014 ... recognized as an industry leader with over 25 years ... winning team leader in the areas related to EDI, ... Mr. Carlson is an Editorial Advisory Board member for ... Council Educator. Blue Fin Group is a management ...
(Date:10/22/2014)... Maureen Salamon HealthDay Reporter ... women undergoing in vitro fertilization (IVF) are only about half ... popular assisted reproduction technique, new research indicates, and the racial ... the study, about 31 percent of white patients became pregnant ... Analyzing more than 4,000 IVF cycles over two years ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 2Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 3Health News:Southern Oregon Is West’s Most Drought Proof Fresh Water Region Say Hiking Guide Authors 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3
... in the January issue of Health Affairs ... the costly chronic disease that affects nearly 26 million ... Health (RSPH) systematically reviewed the published literature and analyzed ... Program (DPP) trial in real-world settings. Published in 2002, ...
... News) -- A drug commonly used to treat patients with ... older than 40 years who have Down syndrome and Alzheimer,s, ... animal studies of the Alzheimer,s drug, memantine, showed promising results ... with Down syndrome aged 40 and older revealed the opposite, ...
... therapies (NRTs) designed to help people stop smoking, specifically nicotine ... in helping smokers quit long-term, even when combined with smoking ... Harvard School of Public Health (HSPH) and the University of ... in an advance online edition of Tobacco Control ...
... HealthDay Reporter , MONDAY, Jan. 9 (HealthDay News) -- There ... research that finds losing a loved one can increase the ... significant other,s death, heart attack risk was 21 times higher ... 2,000 heart attack patients. And within the first week after ...
... , Every year, Americans drink 13.8 billion gallons of soda, ... mass consumption of sugar that is fueling soaring obesity and ... a group of scientists at the University of California, San ... and Columbia University have analyzed the effect of a nationwide ...
... Maureen Salamon HealthDay Reporter , MONDAY, Jan. 9 ... migraine patients as three types of traditional acupuncture, a new ... four groups at nine Chinese hospitals -- one sham acupuncture ... of researchers, including Dr. Fan-rong Liang at Chengdu University in ...
Cached Medicine News:Health News:Diabetes study shines spotlight on lifestyle interventions 2Health News:Diabetes study shines spotlight on lifestyle interventions 3Health News:Alzheimer's Med Seems Ineffective in Those With Down Syndrome 2Health News:Nicotine replacement therapies may not be effective in helping people quit smoking 2Health News:Grief Is a Real Heartbreaker, Study Finds 2Health News:Grief Is a Real Heartbreaker, Study Finds 3Health News:How many lives could a soda tax save? 2Health News:Power of Acupuncture to Ease Migraines Questioned in Study 2Health News:Power of Acupuncture to Ease Migraines Questioned in Study 3
(Date:10/22/2014)... 22, 2014 A new report ... (Product type, Form, End user, Application and Geography) - ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", ... Based on key trends tracked, it is anticipated that ... billion by 2020, registering a CAGR of 6.2% from ...
(Date:10/22/2014)... Pa. , Oct. 22, 2014  With ... their animal health medications, a Global Pharmaceutical and ... Antares serialization technology and turnkey solution to protect ... - http://photos.prnewswire.com/prnh/20141021/153438 Photo ... product that was serialized and aggregated by the ...
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3
... ("Unilife" or "Company") (NASDAQ: UNIS ; ASX: UNS) announced ... fiscal 2012 first quarter ended September 30, 2011 after market trading ... scheduled a conference call for 4:30 p.m. U.S. Eastern Standard Time ... at 8:30 AM AEDT) , to review the Company,s financial ...
... A Continuing Medical Education (CME) workshop, Beating ... risk factors , will be hosted in Jackson, MS ... Cardiovascular Disease, a free course with Continuing Medical ... disease in their practice based upon new and future ...
Cached Medicine Technology:Unilife Corporation to Announce Financial Results For Fiscal 2012 First Quarter on Wednesday, November 9, 2011 2Unilife Corporation to Announce Financial Results For Fiscal 2012 First Quarter on Wednesday, November 9, 2011 3
Hydroview insertion forcep with very thin jaws to allow insertion through tunnel or clear cornea incision. Locking. Made in titanium....
Angled insertion forcep used for the Hydroview lens. Manufactured in titanium....
... This forcep was designed with thinner, ... the Hydroview IOL through a tunnel ... grasp the lens securely, but ... jaws open wide enough to allow ...
Titanium. Forceps designed for insertion of Hydroview foldable intraocular lenses. Unique cross-action design allows for easy insertion of most foldable lens styles....
Medicine Products: